NAPLEX Quiz: Antimicrobial And Opioid Stewardship

What this quiz covers

This quiz focuses on Antimicrobial And Opioid Stewardship, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Weekly hemoglobin A1c
2. Gentamicin serum concentrations (peak/trough or AUC-based monitoring) and serial serum creatinine (correct answer)
3. Daily international normalized ratio (INR)
4. Serum uric acid level every 48 hours

Explanation: This question assesses antimicrobial stewardship monitoring for aminoglycoside therapy in patients with renal impairment during treatment for pyelonephritis. The key patient-specific factor is the baseline chronic kidney disease with reduced creatinine clearance (25 mL/min) and recent gentamicin use, increasing nephrotoxicity risk. Monitoring gentamicin serum concentrations (peak/trough or AUC-based) and serial serum creatinine is critical to ensure therapeutic levels while preventing further renal damage. Weekly hemoglobin A1c is irrelevant without diabetes, daily INR is unnecessary without anticoagulants, and serum uric acid lacks relevance to gentamicin toxicity. A stewardship pearl is to use extended-interval dosing and pharmacokinetic monitoring for aminoglycosides in renal impairment to optimize efficacy and minimize ototoxicity/nephrotoxicity. Always consider patient-specific factors like prior exposure and concurrent nephrotoxins when selecting monitoring parameters in antimicrobial therapy.

Question 2

1. Continue levofloxacin to complete 5 days because symptoms are improving
2. Switch to nitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days and discontinue levofloxacin (correct answer)
3. Add amoxicillin/clavulanate 875/125 mg PO twice daily to levofloxacin for dual coverage
4. Switch to doxycycline 100 mg PO twice daily for 7 days based on E. coli susceptibility to nitrofurantoin

Explanation: This question evaluates antimicrobial de-escalation based on culture susceptibility in uncomplicated urinary tract infection to minimize resistance and adverse effects. The key patient-specific factor is the urine culture showing Escherichia coli resistant to fluoroquinolones but susceptible to nitrofurantoin, with symptoms improving but therapy mismatched. Switching to nitrofurantoin 100 mg PO twice daily for 5 days is best as it aligns with susceptibility, has a favorable profile for cystitis, and avoids unnecessary quinolone exposure. Continuing levofloxacin promotes resistance given documented resistance, adding amoxicillin/clavulanate provides redundant coverage, and doxycycline lacks direct susceptibility support. A clinical pearl is to tailor UTI therapy to local antibiograms and culture results for shortest effective durations. Stewardship frameworks emphasize de-escalation to narrower agents to preserve fluoroquinolone utility for severe infections.

Question 3

1. Continue triple therapy for 10–14 days because meningitis always requires multiple antibiotics
2. De-escalate to ceftriaxone monotherapy (or penicillin G if appropriate) and discontinue vancomycin and ampicillin based on culture results (correct answer)
3. Switch to oral amoxicillin/clavulanate to complete therapy because the organism is penicillin susceptible
4. Add metronidazole for anaerobic coverage and continue current regimen

Explanation: This question tests the antimicrobial stewardship principle of de-escalation, where empirical broad-spectrum antibiotics are narrowed based on culture and susceptibility results to minimize unnecessary exposure and resistance development. The key patient-specific factor is the CSF culture identifying Neisseria meningitidis susceptible to penicillin, with no evidence of Listeria or resistant organisms requiring broader coverage. De-escalating to ceftriaxone monotherapy (or penicillin G) and discontinuing vancomycin and ampicillin is the best choice as it targets the identified pathogen effectively while reducing the risks of toxicity and resistance associated with prolonged unnecessary antibiotics. Continuing triple therapy is incorrect because meningitis does not always require multiple antibiotics once the pathogen is identified and susceptible to narrower agents, and switching to oral amoxicillin/clavulanate is suboptimal as IV therapy is preferred for meningitis to ensure adequate CNS penetration. Adding metronidazole is unnecessary since N. meningitidis is not anaerobic and the regimen already covers typical meningitis pathogens. A key clinical pearl in stewardship is to always review culture results promptly to de-escalate therapy, ideally within 48-72 hours of initiation. Effective de-escalation frameworks involve assessing pathogen identification, susceptibility, and patient response to optimize outcomes and reduce adverse effects.

Question 4

1. Continue vancomycin because it is adequate for MSSA and avoids beta-lactam allergies
2. Switch to cefazolin (or nafcillin/oxacillin) for definitive MSSA bacteremia therapy and discontinue cefepime and vancomycin if no other indication (correct answer)
3. Switch to oral cephalexin immediately because the patient is clinically improving
4. Add daptomycin to vancomycin for dual anti-staphylococcal coverage

Explanation: This question evaluates antimicrobial de-escalation in bacteremia to preferred agents for MSSA once susceptibilities are known. The key patient-specific factor is blood cultures confirming MSSA susceptible to oxacillin, supporting beta-lactam superiority over vancomycin. Switching to cefazolin is best for better outcomes and reduced toxicity in definitive MSSA therapy. Continuing vancomycin is inferior for MSSA, early oral switch is premature without stability, and adding daptomycin is unnecessary. A stewardship pearl is to de-escalate to anti-staphylococcal beta-lactams for MSSA to improve cure rates. Use rapid diagnostics in frameworks to expedite targeted therapy in bacteremia stewardship.

Question 5

1. Continue vancomycin because it covers MSSA and MRSA and is preferred for all staphylococcal infections
2. De-escalate to cefazolin (or nafcillin/oxacillin) and discontinue vancomycin and cefepime if no other indication (correct answer)
3. Switch to daptomycin 6 mg/kg IV daily because it is more potent for pneumonia
4. Add aztreonam 2 g IV every 8 hours for additional gram-negative coverage while continuing current therapy

Explanation: This question tests antimicrobial de-escalation for hospital-acquired pneumonia when cultures confirm a narrower-spectrum option is appropriate. The key patient-specific factor is the sputum culture identifying MSSA susceptible to cefazolin, with negative MRSA PCR supporting vancomycin discontinuation. De-escalating to cefazolin is best as beta-lactams are preferred for MSSA due to superior outcomes over vancomycin. Continuing vancomycin exposes the patient to unnecessary toxicity, daptomycin is suboptimal for pneumonia, and adding aztreonam lacks gram-positive relevance. A stewardship pearl is to prefer anti-staphylococcal penicillins or cefazolin for MSSA infections to improve efficacy and reduce resistance. Use MRSA screening to guide empiric therapy de-escalation in pneumonia stewardship protocols.

Question 6

1. Continue cefepime 2 g IV every 8 hours because higher doses prevent resistance regardless of renal function
2. Reduce cefepime dose/frequency for creatinine clearance 25 mL/min (e.g., 2 g IV every 24 hours per protocol) to reduce neurotoxicity risk (correct answer)
3. Increase cefepime to 2 g IV every 6 hours due to severe infection
4. Switch cefepime to clindamycin 300 mg PO every 6 hours without regard to culture results

Explanation: This question assesses antimicrobial stewardship in dose adjustment for beta-lactams in renal impairment to prevent toxicity during diabetic foot infection treatment. The key patient-specific factor is the reduced creatinine clearance (25 mL/min) in a patient on cefepime, increasing seizure risk from accumulation. Reducing cefepime to 2 g IV every 24 hours is best to maintain efficacy while minimizing neurotoxicity in CKD. Continuing or increasing the dose risks overdose, and switching to clindamycin ignores pending cultures and lacks broad empiric coverage. A stewardship pearl is to adjust renally cleared antibiotics like cefepime based on estimated creatinine clearance using protocols. Always consider patient comorbidities like diabetes when evaluating toxicity risks in antimicrobial dosing frameworks.

Question 7

1. No adjustment is needed because acyclovir is safe at full dose in renal impairment
2. Adjust acyclovir dosing interval for renal impairment (e.g., reduce frequency such as 800 mg PO every 12 hours per protocol for creatinine clearance ~10–25 mL/min) (correct answer)
3. Increase acyclovir to 1,600 mg PO five times daily to overcome reduced renal clearance
4. Switch to nitrofurantoin 100 mg PO twice daily because it is renally cleared

Explanation: This question assesses antimicrobial stewardship in dose adjustment for acyclovir in renal impairment to prevent neurotoxicity. The key patient-specific factor is the low creatinine clearance (18 mL/min) in a non-dialysis CKD patient, necessitating reduced frequency. Adjusting to 800 mg PO every 12 hours is best to avoid accumulation while treating herpes zoster effectively. No adjustment risks seizures, increasing the dose exacerbates toxicity, and switching to nitrofurantoin is inappropriate for zoster. A stewardship pearl is to adjust acyclovir based on ideal body weight and CrCl for safety. Frameworks should include monitoring for CNS effects in renally impaired patients on antivirals.

Question 8

1. Serum creatinine and urine output to assess for nephrotoxicity (correct answer)
2. Thyroid-stimulating hormone (TSH) weekly
3. Serum digoxin concentration
4. Fasting lipid panel

Explanation: This question tests monitoring for antimicrobial-associated toxicities in outpatient vancomycin therapy, particularly with concurrent nephrotoxins. The key patient-specific factor is the rising serum creatinine (from 0.9 to 1.5 mg/dL) during vancomycin and ibuprofen use, signaling potential AKI. Monitoring serum creatinine and urine output for nephrotoxicity is critical to detect and mitigate renal injury promptly. TSH is irrelevant without thyroid agents, digoxin levels lack indication, and lipids are unrelated to vancomycin. A stewardship pearl is to monitor renal function weekly in outpatient vancomycin to adjust dosing and avoid combinations with NSAIDs. Frameworks should include patient education on signs of toxicity for safe long-term antimicrobial use.

Question 9

1. If you feel sleepy, take an extra tablet to sleep through the pain
2. Use nonopioid options first (acetaminophen/ibuprofen if appropriate), avoid driving or operating machinery until you know how it affects you, and store/lock up and dispose of unused tablets properly (correct answer)
3. Crush tablets for faster onset if pain is severe
4. Take the medication on a fixed schedule every 6 hours even if you have no pain to prevent pain from returning

Explanation: This question evaluates opioid stewardship counseling for short-term use post-surgery to promote safe administration and prevent misuse. The key patient-specific factor is the opioid-naive status in a young patient, increasing risks of sedation and dependence if not used judiciously. Counseling on nonopioid priority, avoiding machinery, and proper storage/disposal is most important to minimize harm and diversion. Taking extra for sleepiness risks overdose, crushing alters release, and fixed scheduling promotes unnecessary use. A clinical pearl is to limit opioid quantities to expected needs and encourage multimodal pain relief. Stewardship practices should emphasize education on risks and alternatives to reduce opioid-related harms.

Question 10

1. Audiology assessment and aminoglycoside serum concentrations with serial renal function monitoring (correct answer)
2. Serum magnesium only, because aminoglycosides primarily cause hypomagnesemia
3. Daily creatine kinase (CK) to monitor for myopathy from cefepime
4. Serum amylase and lipase twice weekly

Explanation: This question assesses monitoring for aminoglycoside toxicities in high-risk patients during treatment for ventilator-associated pneumonia. The key patient-specific factor is the elderly patient with prior aminoglycoside exposure, reduced renal function, and COPD, elevating ototoxicity and nephrotoxicity risks. Audiology assessment, tobramycin levels, and serial renal monitoring are critical to prevent irreversible hearing loss and AKI. Serum magnesium alone overlooks broader toxicities, CK is irrelevant to cefepime, and amylase/lipase lack association. A stewardship pearl is to limit aminoglycoside duration and use baseline/periodic audiology in prolonged therapy. Frameworks should risk-stratify patients for enhanced monitoring in antimicrobial stewardship.

Question 11

1. No adjustment is needed because levofloxacin is primarily hepatically cleared
2. Adjust levofloxacin for renal impairment (e.g., 750 mg once, then 750 mg every 48 hours or per protocol for creatinine clearance ~20–49 mL/min) (correct answer)
3. Increase levofloxacin to 750 mg PO twice daily to overcome reduced renal function
4. Switch to vancomycin PO 125 mg four times daily for sinusitis because it is safe in CKD

Explanation: This question tests antimicrobial stewardship in dose adjustment for renally cleared drugs like levofloxacin in CKD to prevent toxicity. The key patient-specific factor is the estimated creatinine clearance of 28 mL/min, requiring interval extension to avoid accumulation and QT prolongation. Adjusting to 750 mg once, then every 48 hours is best per guidelines to maintain efficacy while reducing risks. No adjustment risks overdose despite hepatic metabolism claims, increasing the dose exacerbates toxicity, and switching to vancomycin is inappropriate for sinusitis. A stewardship pearl is to use Cockcroft-Gault for dosing adjustments in CKD. Frameworks should include patient education on adherence to adjusted regimens for safety.

Question 12

1. Continue ceftriaxone because it is effective for most urinary pathogens including Enterococcus
2. Switch to linezolid 600 mg IV/PO every 12 hours (or other VRE-active agent per protocol) and discontinue ceftriaxone (correct answer)
3. Add azithromycin 500 mg daily to ceftriaxone for synergy against Enterococcus
4. De-escalate to cephalexin 500 mg PO four times daily based on urinary penetration

Explanation: This question evaluates antimicrobial de-escalation in complicated UTI when cultures reveal resistance to empiric therapy. The key patient-specific factor is the urine culture showing VRE susceptible to linezolid, rendering ceftriaxone ineffective. Switching to linezolid is best as it provides targeted activity against VRE while discontinuing ineffective agents. Continuing ceftriaxone lacks enterococcal coverage, adding azithromycin offers no synergy, and de-escalating to cephalexin ignores VRE resistance. A stewardship pearl is to reserve linezolid for confirmed VRE to prevent further resistance. Decision frameworks should prioritize susceptibility-guided therapy in UTIs to optimize outcomes.

Question 13

1. Take with grapefruit juice to improve pain control
2. Avoid alcohol and other sedatives; combining with alprazolam increases risk of profound sedation and respiratory depression—use the lowest effective dose and consider nonopioid options first (correct answer)
3. Double the dose if pain is not controlled after the first tablet
4. Store tablets in the bathroom medicine cabinet for easy access and humidity protection

Explanation: This question evaluates opioid stewardship counseling to mitigate risks of misuse, overdose, and drug interactions in short-term opioid therapy. The key patient-specific factor is concurrent alprazolam use, heightening risks of sedation and respiratory depression with hydrocodone. Counseling to avoid alcohol/sedatives, use lowest effective doses, and prioritize nonopioids is most important to prevent life-threatening interactions. Taking with grapefruit juice could unpredictably alter metabolism, doubling the dose risks overdose, and improper storage promotes diversion. A clinical pearl is to screen for CNS depressant interactions using tools like the PDMP before dispensing opioids. Stewardship practices should include patient education on safe use, storage, and disposal to reduce community harm.

Question 14

1. Continue vancomycin plus piperacillin/tazobactam for 14 days to ensure eradication
2. De-escalate to a narrow-spectrum beta-lactam active vs streptococci (e.g., cefazolin or penicillin G) and discontinue broad-spectrum agents (correct answer)
3. Switch to ciprofloxacin 500 mg PO twice daily because it has good skin penetration
4. Add metronidazole 500 mg IV every 8 hours for additional anaerobic coverage despite culture results

Explanation: This question evaluates antimicrobial de-escalation in skin and soft tissue infections based on culture results to minimize broad-spectrum use. The key patient-specific factor is the wound culture showing Streptococcus pyogenes, with no MRSA or gram-negatives, allowing narrower therapy. De-escalating to cefazolin or penicillin G is best as it targets the pathogen effectively while reducing resistance pressure. Continuing broad therapy is unnecessary, ciprofloxacin lacks optimal streptococcal activity, and adding metronidazole ignores aerobic culture results. A stewardship pearl is to tailor SSTI therapy to gram stain and cultures for shortest durations. Use clinical response and source control in decision frameworks to guide de-escalation in antimicrobial stewardship.

Question 15

1. Recommend discontinuing piperacillin/tazobactam if no ongoing gram-negative indication and optimize vancomycin exposure using AUC-guided monitoring to reduce nephrotoxicity (correct answer)
2. Add gentamicin for synergy and continue piperacillin/tazobactam to broaden coverage
3. Increase vancomycin dose to target trough 20–25 mg/L regardless of renal function
4. Continue all antibiotics unchanged and add ketorolac for pain control

Explanation: This question tests antimicrobial stewardship in optimizing vancomycin therapy and de-escalating unnecessary antibiotics to prevent nephrotoxicity in MRSA bacteremia. The key patient-specific factor is the rising serum creatinine (from 0.9 to 1.6 mg/dL) during concomitant vancomycin and piperacillin/tazobactam, with cultures confirming MRSA but no gram-negatives. Recommending discontinuation of piperacillin/tazobactam and AUC-guided vancomycin monitoring is best to reduce nephrotoxicity risk while ensuring adequate MRSA coverage. Adding gentamicin increases toxicity without synergy benefit here, increasing vancomycin to high troughs ignores renal changes, and adding ketorolac risks further kidney injury. A stewardship pearl is to avoid vancomycin-piperacillin/tazobactam combinations when possible due to heightened AKI risk. Use AUC monitoring over troughs for vancomycin to balance efficacy and safety in stewardship practice.

Question 16

1. Recommend continuing TMP/SMX DS twice daily without changes because MRSA requires high dosing in all patients
2. Recommend alternative MRSA therapy (e.g., doxycycline or clindamycin if appropriate) or close potassium/renal monitoring with TMP/SMX due to hyperkalemia risk with lisinopril and spironolactone (correct answer)
3. Add potassium chloride 20 mEq PO daily to prevent TMP/SMX-associated hypokalemia
4. Add ibuprofen 600 mg PO three times daily to improve inflammation and kidney perfusion

Explanation: This question assesses antimicrobial stewardship in managing drug interactions and toxicities in CKD patients during MRSA treatment. The key patient-specific factor is the reduced creatinine clearance (20 mL/min) and baseline hyperkalemia with concurrent lisinopril and spironolactone, increasing TMP/SMX risks. Recommending alternative therapy like doxycycline with close monitoring is best to avoid hyperkalemia and renal worsening. Continuing TMP/SMX ignores interaction risks, adding potassium exacerbates hyperkalemia, and adding ibuprofen risks further AKI. A clinical pearl is to evaluate electrolyte and renal interactions when selecting antibiotics in CKD. Stewardship frameworks should prioritize safer alternatives and monitoring in high-risk patients to prevent adverse events.

Question 17

1. Recommend co-prescribed naloxone, reassess opioid/benzodiazepine combination with prescriber, and consider gradual opioid dose reduction while evaluating for sleep-disordered breathing (correct answer)
2. Increase fentanyl to 75 mcg/hour to reduce awakenings and improve sleep quality
3. Add diphenhydramine 50 mg nightly to counteract opioid-related insomnia while continuing current therapy
4. Abruptly discontinue fentanyl patch today and start codeine 30 mg every 4 hours as needed without taper

Explanation: This question examines opioid stewardship in managing high-risk combinations and potential sleep-disordered breathing in chronic opioid users. The key patient-specific factor is concurrent diazepam and pregabalin with fentanyl, plus symptoms of snoring and sleepiness suggesting central sleep apnea. Recommending naloxone, reassessment of combinations, and taper consideration is best to mitigate overdose and respiratory risks. Increasing fentanyl worsens apnea, adding diphenhydramine heightens sedation, and abrupt discontinuation risks withdrawal. A clinical pearl is to screen for sleep disorders in long-term opioid patients using tools like STOP-BANG. Stewardship frameworks emphasize deprescribing high-risk combos and offering reversal agents like naloxone.

Question 18

1. Use the prescription as written because oxycodone is safe in severe hepatic impairment
2. Avoid acetaminophen entirely and switch to ibuprofen 800 mg PO three times daily scheduled
3. Start with a lower opioid dose and longer interval (e.g., oxycodone 2.5–5 mg per dose with extended dosing interval) and limit total acetaminophen to ≤2 g/day (correct answer)
4. Increase to oxycodone/acetaminophen 10 mg/650 mg every 4 hours as needed due to opioid tolerance in cirrhosis

Explanation: This question examines opioid stewardship in dose adjustment for patients with severe hepatic impairment to prevent toxicity from accumulation. The key patient-specific factor is Child-Pugh C cirrhosis with elevated bilirubin, low albumin, and prolonged INR, indicating reduced hepatic metabolism of opioids and acetaminophen. Starting with a lower oxycodone dose (2.5–5 mg) and extended interval while limiting acetaminophen to ≤2 g/day is best to minimize hepatotoxicity and encephalopathy risk. Using the prescription as written risks overdose due to impaired clearance, avoiding acetaminophen entirely overlooks its utility in multimodal pain control, and increasing the dose ignores tolerance myths in cirrhosis. A clinical pearl is to prefer short-acting opioids at reduced doses in advanced liver disease and monitor for sedation or constipation. Stewardship frameworks should prioritize nonopioid analgesics and regular reassessment in high-risk hepatic patients to enhance safety.

Question 19

1. Continue piperacillin/tazobactam plus vancomycin for a total of 7–10 days to prevent resistance
2. De-escalate to ceftriaxone 1 g IV every 24 hours (or equivalent targeted beta-lactam) and discontinue vancomycin and piperacillin/tazobactam (correct answer)
3. Switch to trimethoprim/sulfamethoxazole DS 1 tablet PO twice daily based on susceptibility to penicillin
4. Add azithromycin 500 mg IV every 24 hours to broaden atypical coverage while continuing current therapy

Explanation: This question tests the principle of antimicrobial de-escalation in empirical therapy for community-acquired pneumonia once culture results guide targeted treatment. The key patient-specific factor is the sputum culture revealing Streptococcus pneumoniae susceptible to penicillin and ceftriaxone, combined with negative MRSA nasal PCR and improving procalcitonin. De-escalating to ceftriaxone 1 g IV every 24 hours is the best choice as it provides effective, narrow-spectrum coverage against the identified pathogen while minimizing unnecessary broad-spectrum antibiotic exposure. Continuing piperacillin/tazobactam plus vancomycin is suboptimal as it promotes resistance without added benefit given the susceptibility profile, and switching to trimethoprim/sulfamethoxazole is inappropriate due to the sulfa allergy and lack of first-line indication for pneumococcal pneumonia. Adding azithromycin is unnecessary as there is no evidence of atypical pathogens, and the regimen already covers typical bacteria adequately. A key stewardship pearl is to de-escalate antibiotics based on culture results and clinical improvement to reduce selective pressure for resistance. Always reassess the need for MRSA coverage using tools like nasal PCR to guide vancomycin discontinuation.

Question 20

1. Continue current oxycodone regimen because the patient has been stable on it for months
2. Recommend initiating a gradual taper (e.g., reduce total daily dose by about 10% per week or slower) with close follow-up and optimize nonopioid therapies (correct answer)
3. Stop oxycodone abruptly today to prevent further constipation and advise using acetaminophen only
4. Increase oxycodone to 15 mg every 4 hours as needed to improve function and reduce breakthrough pain

Explanation: This question evaluates opioid stewardship principles for managing long-term opioid therapy in chronic non-cancer pain, emphasizing risk assessment and tapering. The key patient-specific factor is the history of opioid-related constipation/ileus hospitalization and high daily opioid use (60 mg oxycodone equivalents) for over 8 months. Recommending a gradual taper (e.g., 10% per week) with nonopioid optimization is best as it mitigates withdrawal risks, addresses potential dependence, and aligns with CDC guidelines for high-risk patients. Continuing the current regimen ignores the recent adverse event and dependence risk, while abrupt discontinuation could precipitate severe withdrawal; increasing the dose would exacerbate constipation and overdose risk without improving function. A transferable clinical pearl is to use tools like the PDMP and risk assessments (e.g., ORT) to identify candidates for opioid tapering in chronic pain management. Always incorporate multimodal therapy, including nonopioids and behavioral interventions, to enhance safety and efficacy in opioid stewardship.